Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...

In another positive development for the lung cancer community, NICE has also given its blessing to NHS use of MSD's $25 ...

For the first time, the National Institute for Health and Care Excellence has recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce ...

A treatment that rallies the immune system to destroy cancer raised the survival rate for advanced Hodgkin lymphoma patients ...

It sometimes develops due to lung problems, like respiratory infections, blood clots, or lung cancer. What feels like lung pain may also originate in a nearby structure, such as the chest wall or ...

What’s more, AM-101 improved radiation treatment, slowing down the growth of NSCLC subcutaneous xenograft tumors in mice, by ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

In a potential advance for melanoma patients, researchers at ChristianaCare's Gene Editing Institute have used CRISPR gene ...

Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...

The American College of Radiology advises women who are at average risk for breast cancer to get mammograms annually starting ...

Novocure received a long-sought FDA approval for the use of its Tumor Treating Fields technology against metastatic non-small ...

Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...